WT1 and acute myeloid leukemia: Mutated WT1 in NK-AML was associated with inferior 5-year EFS (30%; CI: 17–43%; Figure S1F), and co-occurrence of mutated WT1 with FLT3-ITD further impacted prognosis (5-year EFS: 22%, CI: 9–39%; Figure 4E).